time to read 2 min read

Kidney cancer-related deaths are expected to drastically increase by over 59% worldwide between 2022 and 2040.1

~435,000 patients

Kidney cancer accounted for ∼ 435,000 patients diagnosed around the world, and 156,000 related deaths in 2022 alone.2

~20-30%

Despite surgical resection, ~20-30% of patients with kidney cancer experience relapse. In 50-60% of cases, the cancer returns with lung metastasis.3

At MSD, we are as committed as ever to reimagining treatment and helping patients in the fight against kidney cancer.

WE’RE GROWING MORE THAN A PORTFOLIO.
WE’RE GROWING HOPE.

MSD has a clear mission to revolutionise the treatment landscape for renal cell carcinoma (RCC) and is dedicated to enhancing patient survival and quality of life during adjuvant therapy.

MSD specialises in providing treatment solutions for a variety of patient types with RCC, with approved indications from early (ES) to late stages (LS) of disease.3-10

Over the years, MSD has spearheaded immunotherapy’s establishment as the standard-of-care adjuvant therapy for intermediate-high or high-risk RCC patients, marking a notable milestone in the field.11

Explore our expanding portfolio

WE’RE GROWING MORE THAN RESEARCH.
WE’RE GROWING POSSIBILITIES.

Our commitment to RCC extends beyond treatment options, as we’re keenly focused on the future, pushing the boundaries of research.

Fuelled by 15+ years of research and 70+ clinical trials,12 we are exploring new molecular targets and therapeutic combinations that might benefit patients who develop resistance to current therapies or experience limited durable response.13,14

MSD also supports the application of Nobel Prize-winning research towards the discovery of innovative medicines, which may have a substantial impact on RCC patients.15,16

Learn more about our science

WE’RE GROWING MORE THAN TREATMENT.
WE’RE GROWING CARE.

MSD is proud and excited to demonstrate both resilience and momentum in delivering innovative therapeutic solutions that address the unmet needs of as many RCC patients as possible.

MSD has reached its 5-year milestone in kidney cancer patient care, contributing to the revolution of the RCC treatment landscape after over 15 years of clinical trials.11,12

We also have meticulously developed patient-focused materials, which are crafted to complement your expertise and empower patients with accessible information that aligns with their care journey.

Join our mission to transform patient care

WE’RE GROWING MORE THAN PARTNERSHIPS.
WE’RE GROWING TRUST.

At MSD, we are determined to continue growing alongside healthcare providers, serving as your dedicated partner in delivering innovative solutions for your patients.

[PLACEHOLDER TO ADD LOCAL INITIATIVES]
[Additional content must be approved locally by the MLR team.]

Discover how we can partner together

ES: early stage; LS: late stage; RCC: renal cell carcinoma.

References:

  1. International Agency for Research on Cancer. Global Cancer Observatory. Kidney. Estimated number of deaths from 2022 to 2040, both sexes, age [0-85+]. Worldwide. Available at: https://gco.iarc.fr/tomorrow/en/dataviz/bubbles types=1&sexes=0&mode=cancer&group_populations=1&multiple_populations=1&multiple_cancers=1&cancers=29&populations=903_904_905_908_909_935&apc=cat_ca20v1.5_ca23v-1.5&group_cancers=1&key=total&show_bar_mode_prop=1&years=2040. Accessed June 2024.
  2. Azawi NH et al. Dan Med J. 2016;63(4).
  3. Motzer RJ et al. J Natl Compr Canc Netw. 2024;22(1):4-16.
  4. Powles T et al. Ann Oncol. 2021;32(12):1511-9.
  5. Rathmell WK et al. J Clin Oncol. 2022;40(25):2957-95.
  6. Keytruda®. Summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Accessed June 2024.
  7. Motzer R et al. N Engl J Med. 2021;384(14):1289-300.
  8. Choueiri TK et al. N Engl J Med. 2021;385(8):683-94.
  9. Rini BI et al. N Engl J Med. 2019;380(12):1116-27.
  10. European Association of Urology. EAU Guidelines on renal cell carcinoma. Available at: https://uroweb.org/guidelines/renal-cell-carcinoma. Accessed June 2024.
  11. Tur J, Webster RM. Nat Rev Drug Discov. 2024;23(1):16-7.
  12. National Institutes of Health. Clinicaltrials.gov. Filters applied: renal cell carcinoma, Merck Sharp, and Dohme. Available at: https://clinicaltrials.gov/search cond=Renal%20Cell%20Carcinoma&term=merck%20sharp%20and%20dohme&page=1. Accessed June 2024.
  13. Choueiri TK et al. Future Oncol. 2023.
  14. Albiges L et al. Ann Oncol. 2023;34:S1329-S30.
  15. The Nobel Prize. Press release for the Nobel Prize in Physiology or Medicine 2019. Available at: https://www.nobelprize.org/prizes/medicine/2019/press-release. Accessed June 2024.
  16. Choueiri TK et al. Nat Med. 2021;27(5):802-5.